Endocrine journal最新文献_第2页

Status of temozolomide use without insurance coverage in patients with aggressive pituitary neuroendocrine tumors. 侵袭性垂体神经内分泌肿瘤患者无保险使用替莫唑胺的现状。

IF 1.3 4区医学

Endocrine journal Pub Date : 2025-07-01 Epub Date: 2025-03-11 DOI: 10.1507/endocrj.EJ24-0727

Atsushi Ishida, Naoko Inoshita, Noriaki Tanabe, Koji Takano, Hideki Shiramizu, Haruko Yoshimoto, Masataka Kato, Go Matsuoka, Shozo Yamada

{"title":"Status of temozolomide use without insurance coverage in patients with aggressive pituitary neuroendocrine tumors.","authors":"Atsushi Ishida, Naoko Inoshita, Noriaki Tanabe, Koji Takano, Hideki Shiramizu, Haruko Yoshimoto, Masataka Kato, Go Matsuoka, Shozo Yamada","doi":"10.1507/endocrj.EJ24-0727","DOIUrl":"10.1507/endocrj.EJ24-0727","url":null,"abstract":"The 2017 World Health Organization classification described aggressive pituitary neuroendocrine tumor (PitNET) as \"a tumor with strong invasiveness and rapid growth, which is difficult to treat with surgery, radiation therapy, or drug therapy,\" which remains a challenge in the treatment of pituitary tumors. Currently, temozolomide (TMZ) is the first-line treatment for aggressive PitNET. However, it is not yet covered by insurance in Japan. Additionally, O6-Methylguanine-DNA Methyltransferase (MGMT) expression can lead to treatment resistance, further complicating treatment selection. We previously demonstrated the effectiveness of combination therapy with capecitabine (CAPTEM) in several cases of aggressive PitNETs. The present study described our experiences with TMZ in 13 patients with aggressive PitNETs (including four patients administered CAPTEM). Pathological examination revealed eight corticotroph, four lactotroph, and one somatotroph tumors. Of these, seven patients are still receiving treatment, and six patients have terminated treatment. The reasons for discontinuation were poor efficacy (three patients), financial reasons (two patients), and patient preference (one patient). No patients required treatment discontinuation owing to adverse events. Furthermore, one case of a lactotroph tumor, which achieved remission with CAPTEM but was discontinued after three years for financial reasons, remains in remission on imaging and maintained normal PRL levels for 15 months after discontinuation. The most significant issue is off-label use. Concern exists that financial constraints may prevent future patients from using TMZ.","PeriodicalId":11631,"journal":{"name":"Endocrine journal","volume":" ","pages":"781-789"},"PeriodicalIF":1.3,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143613504","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Histologically confirmed immunoglobulin G4-related hypophysitis in an adolescent girl: a case report with review of literature. 组织学证实的青春期女孩免疫球蛋白g4相关性垂体炎一例报告并文献复习。

IF 1.3 4区医学

Endocrine journal Pub Date : 2025-06-27 DOI: 10.1507/endocrj.EJ25-0129

Yuto Shimizu, Yuri Mukoyama, Fumihiko Takizawa, Atsushi Ogawa, Tetsushi Ogawa, Noriaki Fukuhara, Masahiko Tosaka, Hiroshi Nishioka, Shinji Ito, Yoichiro Oda, Tsuyoshi Isojima

{"title":"Histologically confirmed immunoglobulin G4-related hypophysitis in an adolescent girl: a case report with review of literature.","authors":"Yuto Shimizu, Yuri Mukoyama, Fumihiko Takizawa, Atsushi Ogawa, Tetsushi Ogawa, Noriaki Fukuhara, Masahiko Tosaka, Hiroshi Nishioka, Shinji Ito, Yoichiro Oda, Tsuyoshi Isojima","doi":"10.1507/endocrj.EJ25-0129","DOIUrl":"https://doi.org/10.1507/endocrj.EJ25-0129","url":null,"abstract":"Hypophysitis is an extremely rare inflammatory condition in children that affects the pituitary gland and infundibulum. Immunoglobulin G4-related hypophysitis (IgG4-RH) is an IgG4-related disease (IgG4-RD) typified by the infiltration of IgG4-positive plasma cells into the pituitary gland, leading to fibrosis and damage. Although IgG4-RD was recently recognized as a defined clinical entity, pediatric cases of IgG4-RD are extremely rare. This report describes a histologically confirmed case of IgG4-RH in a 13-year-old girl. The patient became anorectic after several months of nonspecific symptoms such as headache and fatigue. Detailed examinations, including brain computed tomography (CT), did not detect any causes. However, repeated brain CT revealed pituitary enlargement. Further investigations identified an elevated serum IgG4 level (234 mg/dL, normal range: <118 mg/dL). Pituitary biopsy revealed increased IgG4-positive plasma cell counts in the anterior pituitary gland, fulfilling the diagnostic criteria for IgG4-RH. Steroid treatment dramatically improved her symptoms and reversed pituitary enlargement. A literature review identified 128 pediatric cases of IgG4-RD but only seven cases of pediatric IgG4-RH including our case. Although ophthalmic disease was the most common manifestation, broad clinical presentations were observed, even in pediatric cases. A slight female predominance was suggested in pediatric populations with IgG4-RD, whereas a male predominance was reported in adults. Pediatricians should consider IgG4-RH in the differential diagnosis when encountering patients with nonspecific symptoms because early diagnosis could improve the prognosis of pituitary function. Consequently, necessitating the diseases awareness.","PeriodicalId":11631,"journal":{"name":"Endocrine journal","volume":" ","pages":""},"PeriodicalIF":1.3,"publicationDate":"2025-06-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144505135","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Changes in body mass index during chemotherapy are positively associated with height outcome in childhood cancer survivors of acute lymphoblastic leukemia. 急性淋巴细胞白血病儿童癌症幸存者化疗期间体重指数的变化与身高结局呈正相关。

IF 1.3 4区医学

Endocrine journal Pub Date : 2025-06-26 DOI: 10.1507/endocrj.EJ24-0545

Tamaki Wada, Ayaha Hata, Takatoshi Maeyama, Shinobu Ida, Kohei Higuchi, Maho Sato, Akihisa Sawada, Yuri Etani, Masanobu Kawai

{"title":"Changes in body mass index during chemotherapy are positively associated with height outcome in childhood cancer survivors of acute lymphoblastic leukemia.","authors":"Tamaki Wada, Ayaha Hata, Takatoshi Maeyama, Shinobu Ida, Kohei Higuchi, Maho Sato, Akihisa Sawada, Yuri Etani, Masanobu Kawai","doi":"10.1507/endocrj.EJ24-0545","DOIUrl":"https://doi.org/10.1507/endocrj.EJ24-0545","url":null,"abstract":"Impaired linear growth is an important morbidity in childhood cancer survivors (CCS); however, chemotherapy-associated factors that affect height outcomes remain elusive. Accordingly, we conducted a single-center, retrospective cohort study that included survivors of childhood-onset acute lymphoblastic leukemia (ALL) diagnosed between 2002 and 2021 who achieved complete remission through chemotherapy alone. Anthropometric parameters and treatment protocols were evaluated based on medical records. Individuals with background disorders or impaired growth were excluded from the study. Associations between anthropometric parameters during chemotherapy and height standard deviation scores (height-SDS) at the current visit were investigated. The results are expressed as the median (interquartile range). Seventy-three individuals (males, N = 44) were included in the study. The median age (years) at diagnosis, end of chemotherapy, and current visit were 4.2 (3.2 to 7.9), 6.3 (5.1 to 10.0), and 15.9 (11.4 to 19.2), respectively. Height-SDS at diagnosis was -0.25 (-0.65 to 0.35), which significantly declined during chemotherapy and recovered thereafter, resulting in a current height-SDS of -0.31 (-0.84 to 0.22). The height-SDS at the investigated time points and its changes during chemotherapy did not differ among the treatment protocols. Multivariate analysis revealed that height-SDS at the current visit was positively associated with changes in body mass index (BMI)-SDS during chemotherapy (β = 0.22, p = 0.01) after adjusting for sex, current age, height-SDS at diagnosis, changes in height-SDS during chemotherapy, and treatment protocols. Since changes in BMI are potentially influenced by nutritional status, our results may underscore the importance of nutritional status during chemotherapy on height outcomes in childhood ALL survivors.","PeriodicalId":11631,"journal":{"name":"Endocrine journal","volume":" ","pages":""},"PeriodicalIF":1.3,"publicationDate":"2025-06-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144505134","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Imbalances in adrenal hormones and their effects on bone metabolism. 肾上腺激素失衡及其对骨代谢的影响。

IF 1.3 4区医学

Endocrine journal Pub Date : 2025-06-21 DOI: 10.1507/endocrj.EJ25-0117

Maki Yokomoto-Umakoshi, Hironobu Umakoshi, Yoshihiro Ogawa

{"title":"Imbalances in adrenal hormones and their effects on bone metabolism.","authors":"Maki Yokomoto-Umakoshi, Hironobu Umakoshi, Yoshihiro Ogawa","doi":"10.1507/endocrj.EJ25-0117","DOIUrl":"10.1507/endocrj.EJ25-0117","url":null,"abstract":"Adrenal hormones are essential for maintaining physiological homeostasis; however, imbalances in their production can significantly impact bone metabolism. This review examines how adrenal hormone dysregulation affects bone health, focusing on the following three key pathological conditions: autonomous cortisol secretion, primary aldosteronism, and pheochromocytoma/paraganglioma. Each disorder exerts distinct effects on bone metabolism, contributing to reduced bone mass, deteriorated bone quality, and increased fracture risk. Recent advances in steroid profiling and single-cell transcriptome analysis have revealed that, in adrenocortical adenomas-such as cortisol-producing and aldosterone-producing adenomas-multiple steroid hormones contribute to these effects rather than a single hormone. Additionally, age-related changes in steroid hormones, particularly the progressive decline in dehydroepiandrosterone sulfate production and alterations in cortisol circadian rhythm, may contribute to age-associated bone fragility. This review summarizes the effects of adrenal hormone imbalances on bone metabolism in both pathological conditions and aging, which may contribute to understanding adrenal-related osteoporosis.","PeriodicalId":11631,"journal":{"name":"Endocrine journal","volume":" ","pages":""},"PeriodicalIF":1.3,"publicationDate":"2025-06-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144368710","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

46,XY 17 alpha-hydroxylase/17,20 lyase deficiency with breast development: A case report and literature review. [6] XY -羟化酶/裂解酶缺乏症与乳腺发育：1例报告及文献复习。

IF 1.3 4区医学

Endocrine journal Pub Date : 2025-06-20 DOI: 10.1507/endocrj.EJ24-0715

Sayaka Kawashima, Hirohito Shima, Yohei Satake, Naomi Shiga, Masahito Tachibana, Junko Kanno, Atsuo Kikuchi

{"title":"46,XY 17 alpha-hydroxylase/17,20 lyase deficiency with breast development: A case report and literature review.","authors":"Sayaka Kawashima, Hirohito Shima, Yohei Satake, Naomi Shiga, Masahito Tachibana, Junko Kanno, Atsuo Kikuchi","doi":"10.1507/endocrj.EJ24-0715","DOIUrl":"10.1507/endocrj.EJ24-0715","url":null,"abstract":"Individuals with the 46,XY karyotype and 17 alpha-hydroxylase/17,20 lyase deficiency (17OHD) may develop disorders/differences of sex development (DSD) accompanied by delayed puberty or primary amenorrhea. Glucocorticoid replacement is required to normalize hypertension in 17OHD, which highlights the importance of appropriate diagnostics for the selection of relevant treatment. A 16-year-old female with primary amenorrhea was found to have the 46,XY karyotype. Since the patient had spontaneous breast development, she was initially diagnosed with complete androgen insensitivity syndrome (CAIS). However, CAIS was subsequently ruled out due to an extremely low testosterone level, and 17OHD was suspected because of hypertension with low plasma renin activity, an elevated adrenocorticotropic hormone (ACTH) level, and decreased cortisol level. Two variants in CYP17A1, which were previously reported to be pathogenic, were detected and eventually confirmed the diagnosis of 17OHD. We reviewed 198 reported cases of 46,XY with 17OHD, and found spontaneous breast development in 9 of 129 (7.0%) individuals with typical female external genitalia. Although gonadal hormone production is impaired in 17OHD, 17OHD needs to be considered in differential diagnostics of 46,XY DSD even with spontaneous breast development.","PeriodicalId":11631,"journal":{"name":"Endocrine journal","volume":" ","pages":""},"PeriodicalIF":1.3,"publicationDate":"2025-06-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144368709","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

What comparative endocrinology tells us about the original function of the insulin superfamily. 比较内分泌学告诉我们胰岛素超家族的原始功能。

IF 1.3 4区医学

Endocrine journal Pub Date : 2025-06-20 DOI: 10.1507/endocrj.EJ25-0213

Yoshio Takei

{"title":"What comparative endocrinology tells us about the original function of the insulin superfamily.","authors":"Yoshio Takei","doi":"10.1507/endocrj.EJ25-0213","DOIUrl":"10.1507/endocrj.EJ25-0213","url":null,"abstract":"Comparative endocrinology is a research subfield in endocrinology that delves into deeper understanding of the endocrine system from an evolutionary or phylogenetic perspective. To date, this approach has contributed significantly to the development of endocrinology by elucidating the evolutionary history of hormone molecules and their functions from invertebrates to vertebrates. In this review, the author initially introduces how the comparative approach has expanded and enlightened the view in endocrinology using the concept of hormones as an example. The expansion of the hormone concept blurs boundaries between signaling molecules of the three homeostatic systems, namely, the endocrine, nervous, and immune systems. Subsequently, the evolutionary history of the endocrine system is introduced in terms of both molecules and functions using the insulin superfamily as a model. This hormone family is one of the most ancient hormonal systems in animal (metazoan) phylogeny and the homologous hormones are identified in the most ancient metazoans such as sponges and hydra. In addition, this hormonal system was chosen as a topic of this review, because insulin is one of the most focused research topics in modern medicine in relation to insulin resistance and metabolic syndrome. Finally, the ancestral molecule of the insulin superfamily and its original or essential function will be discussed with some speculations to illustrate the value and joy of comparative studies that can create an original concept of the endocrine system from the evolutionary viewpoint. The comparative approach certainly helps deeper understanding of the insulin superfamily of humans.","PeriodicalId":11631,"journal":{"name":"Endocrine journal","volume":" ","pages":""},"PeriodicalIF":1.3,"publicationDate":"2025-06-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144368711","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Safety management in Cushing syndrome during osilodrostat treatment based on morning blood cortisol level. 基于清晨血皮质醇水平的奥西洛他汀治疗库欣综合征的安全管理。

IF 1.3 4区医学

Endocrine journal Pub Date : 2025-06-19 DOI: 10.1507/endocrj.EJ24-0696

Takuyuki Katabami, Ren Matsuba, Tomoyuki Nagasaka, Yutaro Yamamoto, Kensuke Sakai, Masakatsu Sone

{"title":"Safety management in Cushing syndrome during osilodrostat treatment based on morning blood cortisol level.","authors":"Takuyuki Katabami, Ren Matsuba, Tomoyuki Nagasaka, Yutaro Yamamoto, Kensuke Sakai, Masakatsu Sone","doi":"10.1507/endocrj.EJ24-0696","DOIUrl":"https://doi.org/10.1507/endocrj.EJ24-0696","url":null,"abstract":"Osilodrostat dosage is adjusted based on 24-h urinary free cortisol (UFC) levels. However, approximately 1 week is required to obtain the results. In contrast, serum cortisol levels are available soon after sampling, allowing the determination of osilodrostat doses promptly. However, this issue remains poorly understood. Therefore, this study aimed to determine whether a simultaneous assay of serum cortisol and UFC concentrations is useful in patients with Cushing syndrome (CS) receiving osilodrostat. This was a retrospective cross-sectional study. A total of 71 paired samples in six patients with CS during osilodrostat treatment were analyzed in this study. The 24-h urine sample collection was started from the day before blood sampling, and UFC and morning serum cortisol levels were measured on the same day. Commercially available immunoassay kits were used for the hormone measurements. A significant positive correlation between morning cortisol levels and UFC levels was observed. Receiver operating characteristic analysis showed a cut-off of 21.5 μg/dL for serum cortisol as the best indicator to predict high UFC levels. The cut-off secured UFC samples >3× the upper limit of normal. However, the positive predictive value of serum cortisol levels in predicting low UFC was considerably low. A serum cortisol level <5.0 μg/dL, which is often used to suggest adrenal insufficiency, captured patients with hypocortisolism even when the serum cortisol and UFC results were discordant. Simultaneous measurements of single morning serum cortisol and UFC levels on the same day will promote safety in patients with CS who are being treated with osilodrostat.","PeriodicalId":11631,"journal":{"name":"Endocrine journal","volume":" ","pages":""},"PeriodicalIF":1.3,"publicationDate":"2025-06-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144324801","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

A case of mineralocorticoid intermediate-producing sarcomatoid adrenal cortical carcinoma: case report and review of literature. 肾上腺皮质中矿皮质激素产生肉瘤样癌1例报告并文献复习。

IF 1.3 4区医学

Endocrine journal Pub Date : 2025-06-18 DOI: 10.1507/endocrj.EJ24-0687

Maki Kanzawa, Miki Watanabe, Masaaki Yamamoto, Tomoko Nishigaki, Masaki Suzuki, Hidenori Fukuoka, Tomoaki Terakawa, Katsumi Shigemura, Hiroki Shimada, Yasuhiro Nakamura, Wataru Ogawa, Tomoo Itoh

{"title":"A case of mineralocorticoid intermediate-producing sarcomatoid adrenal cortical carcinoma: case report and review of literature.","authors":"Maki Kanzawa, Miki Watanabe, Masaaki Yamamoto, Tomoko Nishigaki, Masaki Suzuki, Hidenori Fukuoka, Tomoaki Terakawa, Katsumi Shigemura, Hiroki Shimada, Yasuhiro Nakamura, Wataru Ogawa, Tomoo Itoh","doi":"10.1507/endocrj.EJ24-0687","DOIUrl":"https://doi.org/10.1507/endocrj.EJ24-0687","url":null,"abstract":"Sarcomatoid adrenal cortical carcinoma (SACC) is an extremely rare histological subtype accounting for only 0.2% of all adrenal cortical carcinomas. Most reported cases of SACC are nonfunctional, showing a biphasic histological pattern with both epithelial adrenocortical carcinoma and sarcomatous components, which are often associated with poor prognosis. Herein, we report a unique case of SACC with characteristics distinct from those previously documented. A 66-year-old man presented with uncontrolled hypertension, night sweats, exertional dyspnea, and palpitations. Imaging revealed an 11 cm mass in the left adrenal gland. Laboratory results indicated hypokalemia with suppressed plasma renin and aldosterone levels and the presence of mineralocorticoid intermediates, notably elevated deoxycorticosterone (DOC), detected via LC-MS/MS. The patient underwent a left adrenalectomy. Histologically, the tumor consisted solely of spindle cells without the typical adrenocortical carcinoma components. Immunohistochemical analysis demonstrated partial positivity for steroidogenic enzymes, including 3β-hydroxysteroid dehydrogenase, cytochrome P450 family 21 subfamily A member 2 (CYP21A2) and cytochrome P450 family 11 subfamily B member 1 (CYP11B1). This finding was consistent with RNA expression analysis, supporting the synthesis of mineralocorticoid intermediates within the tumor. However, the discrepancy between the measured steroid intermediate metabolites and enzyme expression patterns in the tumor, as indicated by immunostaining and mRNA levels, suggests that the steroid production pathway in this tumor remains partially unclear. Two years postoperatively, the patient has remained free from recurrence or metastasis. This case holds particular value, as it is the first report to describe hormone production in a SACC composed solely of spindle cells.","PeriodicalId":11631,"journal":{"name":"Endocrine journal","volume":" ","pages":""},"PeriodicalIF":1.3,"publicationDate":"2025-06-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144324800","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

A 10-year observational study of the effects of serum 25OH vitamin D levels on the onset of prediabetes at a preventive medicine research center. 在预防医学研究中心对血清25OH维生素D水平对前驱糖尿病发病影响的10年观察研究。

IF 1.3 4区医学

Endocrine journal Pub Date : 2025-06-14 DOI: 10.1507/endocrj.EJ25-0007

Kaoru Ogawa, Jun Ogino, Riri Oh, Yukie Sakuma, Koji Takemura, Yoshifumi Suzuki, Yukie Ito, Yuko Endo, Haruhisa Shimura, Kiyoe Kiuchi, Saburo Watanabe, Yasunori Sato, Shouji Yoshida, Naotake Hashimoto

{"title":"A 10-year observational study of the effects of serum 25OH vitamin D levels on the onset of prediabetes at a preventive medicine research center.","authors":"Kaoru Ogawa, Jun Ogino, Riri Oh, Yukie Sakuma, Koji Takemura, Yoshifumi Suzuki, Yukie Ito, Yuko Endo, Haruhisa Shimura, Kiyoe Kiuchi, Saburo Watanabe, Yasunori Sato, Shouji Yoshida, Naotake Hashimoto","doi":"10.1507/endocrj.EJ25-0007","DOIUrl":"https://doi.org/10.1507/endocrj.EJ25-0007","url":null,"abstract":"We report the findings of a 10-year study that followed the relationship between serum 25-hydroxyvitamin D (25OH vitamin D) levels and the onset of prediabetes, analyzed based on sex. One hundred eighty-seven participants were followed who had a baseline hemoglobin A1c (HbA1c) value below 6.0% and fasting plasma glucose level below 100 mg/dL. The cut-off values for vitamin D concentration were 27.7 ng/mL for men and 17.1 ng/mL for women, based on the receiver operating characteristic curve. The prediabetes incidence was significantly higher in women with a vitamin D concentration ≤17.1 ng/mL [HR = 7.08 (2.08-24.2), p = 0.002] than in men with a concentration ≤27.7 ng/mL [HR = 2.30 (0.63-8.35), p = 0.21], based on the cumulative incidence function curve. Multivariate analysis revealed that an abdominal circumference ≥90 cm and 25OH vitamin D concentration ≤17.1 ng/mL were independent, significant and intervenable risk factors for prediabetes in women. Low levels of vitamin D in women can be a predictive factor in the development of diabetes after 10 years.","PeriodicalId":11631,"journal":{"name":"Endocrine journal","volume":" ","pages":""},"PeriodicalIF":1.3,"publicationDate":"2025-06-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144301377","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

A questionnaire survey of thyroid specialists in Japan on the use of thyroid hormones in hypothyroid and euthyroid patients. 日本甲状腺专家对甲状腺功能减退和甲状腺功能正常患者使用甲状腺激素的问卷调查。

IF 1.3 4区医学

Endocrine journal Pub Date : 2025-06-10 DOI: 10.1507/endocrj.EJ25-0106

Yuji Nagayama, Junichi Tajiri, Tsukasa Murakami, Natsuko Watanabe, Shinya Sato, Hisakazu Shindo, Seigo Tachibana, Roberto Attanasio, Enrico Papini, Petros Perros, Endre V Nagy, Laszlo Hegedüs, Koichi Ito, Hiroyuki Yamashita

{"title":"A questionnaire survey of thyroid specialists in Japan on the use of thyroid hormones in hypothyroid and euthyroid patients.","authors":"Yuji Nagayama, Junichi Tajiri, Tsukasa Murakami, Natsuko Watanabe, Shinya Sato, Hisakazu Shindo, Seigo Tachibana, Roberto Attanasio, Enrico Papini, Petros Perros, Endre V Nagy, Laszlo Hegedüs, Koichi Ito, Hiroyuki Yamashita","doi":"10.1507/endocrj.EJ25-0106","DOIUrl":"https://doi.org/10.1507/endocrj.EJ25-0106","url":null,"abstract":"Levothyroxine (LT4) is the established treatment for hypothyroidism but some controversies, such as whether combining it with liothyronine (LT3) for hypothyroid patients and whether prescribing it to euthyroid patients, exist on its use. This survey was conducted to investigate current trends about thyroid hormone use in hypothyroid and euthyroid patients in Japan. Members of the Japan Thyroid Association (JTA) were invited to participate in an online questionnaire based on the THESIS (Treatment of Hypothyroidism in Europe by Specialists: An International Survey) survey. Anonymous responses from 207 of 874 (23.7%) JTA-certified thyroid specialists were analyzed. LT4 was the first line treatment for hypothyroidism by all respondents. 18.8% and 28.0% would also use LT3 and LT3 + LT4 combination, respectively. LT3 + LT4 combination was preferred for patients on LT4 with residual symptoms or low serum T3 levels. Psychological factors and comorbidities were considered as the main contributors to residual symptoms. Respondents would prescribe thyroid hormones in euthyroid subjects for female infertility with positive anti-thyroid antibodies (46.9%), for Hashimoto's disease with a huge goiter (29.0%), and for pregnant or infertile women with TSH between 2.5-4 mU/L irrespective of anti-thyroid antibody status (43.0 and 76.8%, and 46.9 and 77.3%, respectively). In conclusion, Japanese thyroid specialists chose LT4 as first line treatment for hypothyroidism in accordance with current guidelines. The use of LT3 + LT4 combination is less frequent in Japan than in other countries, whereas the use of thyroid hormones for non-hypothyroid indications is similarly high worldwide, which is not necessarily in accord with pertinent society guidelines.","PeriodicalId":11631,"journal":{"name":"Endocrine journal","volume":" ","pages":""},"PeriodicalIF":1.3,"publicationDate":"2025-06-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144274459","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0